Carl Heneghan

And so I think this is an incredibly interesting issue and shows us the failure to say we have evidence here 10 years in.

And I actually have to think, you know, as a practitioner, is there's no sort of standard record where I think, yeah, actually, we're pushing this, we're checking, are you taking them at night?

Here's our recommendation.

So this allows us to think differently about implementation research and what we do next.

Well, we have tested it in statins, and statins, it's recommended you take them at night.

But to be honest with you, there are so many issues with statins right now, we should leave that for another programme.

So I picked this one because it's a really short title.

Antipsychotics for Preventing Delirium in Hospitalised Adults.

Really nice title.

But what's interesting about this is most people in hospital will know about delirium, a clinical syndrome.

marked by acute and fluctuation disturbance in attention and cognition.

It affects the elderly, but it happens after operations or in acute settings, particularly in critical care units.

And what this systematic review shows is that there's no data in sedative effects or delirium duration or length of stay if you use antipsychotics like haloperidol or the second generation antipsychotics compared to placebo.

And it's basically saying for prevention, there's no evidence.

And then there's another review that says for treatment updated and you get similar effects.

There's no evidence to show you should be using these antipsychotics.

And I thought that was really interesting that actually they claim that they're still being used, but the FDA has no approved treatment for delirium.

Sign guidelines say there's ineffective evidence.

Cochrane Review shared there's no difference in critically ill patients.

Yet when I go to the NICE guideline.